The $299 device claims more than passive tracking: it modifies deep sleep through real-time auditory stimulation. For cognitive performance, the distinction matters. Slow-wave activity is the marker NextSense associates with "increased feelings of restoration and better cognitive performance"—not a metric you can infer from heart rate alone.
The Mechanism
Standard wearables rely on PPG: light sensors detecting cardiovascular changes as a proxy for sleep stages. Smartbuds place EEG sensors inside the earbuds themselves, recording the slow oscillations linked to deep sleep.
- As the brain transitions to sleep, dominant brainwaves get slower.
- NextSense's head of product Caitlin Shure, MA, PhD, states the device uses "the same kind of signals that are being looked at if you get a sleep study in the lab."
- The intervention is called slow-wave enhancement: targeted pink noise delivered during sleep to nudge brain waves into a more restorative pattern.
This is not a generic white-noise machine. The product couples pink noise to the user's actual brain state in real time.
The Field Test
The Popsugar tester reports a rocky onboarding. The first night used an oversized tip; the app flagged poor sensor contact and recommended a smaller attachment. After correction, the device surfaced metrics most consumers have never accessed: slow-wave count, total wakes, and sleep efficiency.
The diagnostic value exceeded the stimulation effect. The tester discovered their eight-hour nights contained less slow-wave activity than assumed—subjective duration and objective restorative sleep diverged. For anyone tracking readiness scores, this is the variable to interrogate.
The Broader Pattern
Smartbuds fit a category trajectory: consumer tools moving from indirect inference to direct neural measurement. ScienceDaily separately reported that researchers mapped the craving-reduction effects of GLP-1 agonists (Ozempic, Wegovy) to the lateral septum—a region linking hippocampal memory inputs with reward processing. The discovery could open new approaches to treating addiction and obesity by targeting a brain region outside the standard dopamine-centric reward model.
Both developments point to the same inflection: behavior is downstream of identifiable neural mechanisms. The open question is whether direct interfacing scales beyond the lab and the prescription pad.